Table 3. The 3- and 5-Year Efficacy Results (Median Follow-up of 5.5 Years).
| End Points | No. of Events | 3 y | 5 y | ||
|---|---|---|---|---|---|
| Estimate, % (95% CI) | No. at Risk | Estimate, % (95% CI) | No. at Risk | ||
| IBRa | 4 | 3.4 (0.6-10.7) | 52 | 5.2 (1.4-13.2) | 46 |
| MFb | 7 | 5.2 (1.3-13.1) | 51 | 10.5 (4.2-20.1) | 43 |
| DMFS | 3 | 94.8 (84.8-98.3) | 53 | 94.8 (84.8-98.3) | 48 |
| OS | 3 | 94.8 (84.8-98.3) | 53 | 94.8 (84.8-98.3) | 48 |
Abbreviations: DMFS, distant metastasis–free survival; IBR, in-breast recurrence; MF, mastectomy failure; OS, overall survival.
a
Two within and 2 outside treatment field.
b
Four for IBRs, 2 for nonhealing wounds, and 1 bilateral for contralateral breast failure.